Correlation between the Expression of Interleukin-6, STAT3, E-Cadherin and N-Cadherin Protein and Invasiveness in Nonfunctional Pituitary Adenomas

Abstract

Objective This study aimed to investigate the expression of interleukin (IL)-6, signal transducer and activator of transcription 3 (STAT3), epithelial-cadherin (E- cadherin) and neural-cadherin (N-cadherin) proteins in nonfunctional pituitary adenomas, and their correlation with invasiveness.

Methods Thirty cases of nonfunctional pituitary adenoma pathological wax specimens were selected from our hospital, including 20 cases of invasive nonfunctional pituitary adenoma (INFPA) and 10 noninvasive nonfunctional pituitary adenomas (NNFPAs). Envision was used to detect IL-6, STAT3, E-cadherin , and N-cadherin in specimens. Statistical methods were used to analyze the correlation between the four proteins and the Knosp classification of nonfunctional pituitary adenomas.

Result IL-6 and STAT3 were highly expressed in INFPAs but poorly expressed in NNFPAs. E-cadherin expression in INFPAs was lower than that in NNFPAs. N-cadherin was positive or strongly positive in both groups. Spearman's correlation analysis showed that the expression of IL-6 and STAT3 was positively correlated with Knosp's classification, whereas the expression of E-cadherin was negatively correlated with Knosp classification. Meanwhile, the expression of N-cadherin was not correlated with Knosp's classification.

Conclusion The expression of the IL-6, STAT3, E-cadherin proteins were associated nonfunctional pituitary adenomas. However, the expression of N-cadherin was not correlated with nonfunctional pituitary adenomas.

Keywords

pituitary adenoma - interleukin-6 - STAT3 - E-cadherin

Publication History

Received: 23 April 2019

Accepted: 13 September 2019

Article published online:
05 December 2019

• References

• 1 Theodros D, Patel M, Ruzevick J, Lim M, Bettegowda C. Pituitary adenomas: historical perspective, surgical management and future directions. CNS Oncol 2015; 4 (06) 411-429
• 2 Zhenye L, Chuzhong L, Youtu W. et al. The expression of TGF-β1, Smad3, phospho-Smad3 and Smad7 is correlated with the development and invasion of nonfunctioning pituitary adenomas. J Transl Med 2014; 12: 71
• 3 Manojlovic-Gacic E, Engström BE, Casar-Borota O. Histopathological classification of non-functioning pituitary neuroendocrine tumors. Pituitary 2018; 21 (02) 119-129
• 4 Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 1982; 95 (01) 333-339
• 5 Wang J, Zhang Z, Li R. et al. ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway. Biomed Pharmacother 2018; 97: 1066-1077
• 6 Wang H, Wang G, Gao Y. et al. Lnc-SNHG1 activates the TGFBR2/SMAD3 and RAB11A/Wnt/β-Catenin pathway by sponging MiR-302/372/373/520 in invasive pituitary tumors. Cell Physiol Biochem 2018; 48 (03) 1291-1303
• 7 Bollrath J, Phesse TJ, von Burstin VA. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15 (02) 91-102
• 8 Klampfer L. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 2011; 11 (04) 451-464
• 9 Smith AP, Verrecchia A, Fagà G. et al. A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 2009; 28 (03) 422-430
• 10 Feng J, Yu S-Y, Li C-Z, Li ZY, Zhang YZ. Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas. Mol Cell Endocrinol 2016; 436: 195-203
• 11 Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive pituitary tumors. Neuroendocrinology 2015; 101 (02) 87-104
• 12 Li CZ, Zhang YZ. Classification and interpretation of WHO pituitary tumors in the 2017 edition. Chin. J Neurosurg 2018; 34 (01) 1-5
• 13 Losa M, Franzin A, Mangili F. et al. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 2000; 47 (06) 1313-1318
• 14 Lee CC, Yang HC, Chen CJ. et al. Empirical versus progression-guided stereotactic radiosurgery for non-functional pituitary macroadenomas after subtotal resection. J Neurooncol 2019; 142 (02) 291-297
• 15 Sheehan JP, Starke RM, Mathieu D. et al. Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg 2013; 119 (02) 446-456
• 16 Pomeraniec IJ, Dallapiazza RF, Xu Z, Jane Jr. JA, Sheehan JP. Early versus late Gamma Knife radiosurgery following transsphenoidal resection for nonfunctioning pituitary macroadenomas: a matched cohort study. J Neurosurg 2016; 125 (01) 202-212
• 17 Sheehan J, Lee CC, Bodach ME. et al. Congress of neurological surgeons systematic review and evidence-based guideline for the management of patients with residual or recurrent nonfunctioning pituitary adenomas. Neurosurgery 2016; 79 (04) E539-E540
• 18 Chen LM, Liu PY, Chen YA. et al. Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression. Sci Rep 2017; 7 (01) 11864-11869
• 19 Wu D, Cheng J, Sun G. et al. p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma. Oncotarget 2016; 7 (24) 36539-36550
• 20 Leng K, Xu Y, Kang P. et al. Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6/STAT3/VEGFA signaling pathway. Cell Death Dis 2019; 10 (04) 262
• 21 Tanase C, Codrici E, Popescu ID. et al. Angiogenic markers: molecular targets for personalized medicine in pituitary adenoma. Per Med 2013; 10 (06) 539-548
• 22 Yuanyang L, Jiabin Z, Kai W. et al. Expression of IL-6 and its relationship to microvessel density and invasiveness of pituitary adenomas. Chinese Journal of Minimally Invasive Neurosurgery 2014; 19 (09) 424-426
• 23 Yao J, Qian CJ, Ye B. et al. Signal transducer and activator of transcription 3 signaling upregulates fascin via nuclear factor-κB in gastric cancer: Implications in cell invasion and migration. Oncol Lett 2014; 7 (03) 902-908
• 24 Marylynn S, Huang X-Y, Zhang J. Jillian, Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. J Biol Chem 2011; 286 (388) 86-93
• 25 Machesky LM, Li A. Fascin: invasive filopodia promoting metastasis. Commun Integr Biol 2010; 3 (03) 263-270
• 26 Mao X, Duan X, Jiang B. Fascin induces epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating wnt/β-catenin signaling. Med Sci Monit 2016; 22: 3479-3485
• 27 Rodrigues PC, Sawazaki-Calone I, Ervolino de Oliveira C. et al. Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma. Oncotarget 2017; 8 (43) 74736-74754
• 28 Li Y, Wang Y, Xu J. et al. Correlation between Fascin Ki-67 expression and tumor invasion in pituitary adenomas. Chinese Journal of Practical Nervous Diseases 2018; 21 (09) 6-11
• 29 Kang L, Tian T, Yi Z. et al. Scutellarin inhibits proliferation and invasion of hepatocellular carcinoma cells via down-regulation of JAK2/STAT3 pathway. J Cell Mol Med 2019; 00: 1-5
• 30 Tu Y, Zhong Y, Fu J. et al. Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol 2011; 28 (01) 15-23
• 31 Valiulyte I, Steponaitis G, Skiriute D, Tamasauskas A, Vaitkiene P. Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma. BMC Med Genet 2017; 18 (01) 72
• 32 Zhou C, Jiao Y, Wang R, Ren SG, Wawrowsky K, Melmed S. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. J Clin Invest 2015; 125 (04) 1692-1702
• 33 Kourtidis A, Lu R, Pence LJ, Anastasiadis PZ. A central role for cadherin signaling in cancer. Exp Cell Res 2017; 358 (01) 78-85
• 34 Sang S, Zhang C, Shan J. Pyrroline-5-carboxylate reductase 1 accelerates the migration and invasion of nonsmall cell lung cancer in vitro. Cancer Biother Radiopharm 2019; 34 (06) 380-387
• 35 Zhou K, Jin H, Luo Y. Expression and significance of E-cadherin and β-catenins in pituitary adenoma. Int J Surg Pathol 2013; 21 (04) 363-367
• 36 Colella B, Faienza F, Di Bartolomeo S. EMT regulation by autophagy: a new perspective in glioblastoma biology. Cancers (Basel) 2019; 11 (03) 312
• 37 Appolloni I, Barilari M, Caviglia S, Gambini E, Reisoli E, Malatesta P. A cadherin switch underlies malignancy in high-grade gliomas. Oncogene 2015; 34 (15) 1991-2002
• 38 Pal Ipsita, Rajesh Y, Banik Payel. et al. Prevention of epithelial to mesenchymal transition in colorectal carcinoma by regulation of the E-cadherin-β-catenin-vinculin axis. Cancer Lett 2019; 452: 254-263
• 39 Gloushankova NA, Zhitnyak IY, Rubtsova SN. Role of epithelial-mesenchymal transition in tumor progression. Biochemistry (Mosc) 2018; 83 (12) 1469-1476
• 40 Tanase C, Albulescu R, Codrici E. et al. Decreased expression of APAF-1 and increased expression of cathepsin B in invasive pituitary adenoma. OncoTargets Ther 2014; 8: 81-90